New therapeutic strategies targeting transmembrane signal transduction in the immune system

Cell Adhesion and Migration

Volumn 4, Issue 2, 2010, Pages 255-267

  Sigalov, Alexander B ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cell signaling; Immune system; Immunotherapy; Multichain immune recognition receptor; Receptors; RTK; Single chain receptor; TCR; Therapeutic targets; Transmembrane interactions

Indexed keywords

ADJUVANT; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; GLYCOPROTEIN VI; GLYCOPROTEIN VI RECEPTOR; GLYCOPROTEIN VI RECEPTOR INHIBITOR; IMMUNOSUPPRESSIVE ACID PROTEIN; MEMBRANE PROTEIN; MULTICHAIN IMMUNE RECOGNITION RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; OKT 3; PLATELET INHIBITOR; PROTEIN TYROSINE KINASE; SIGNAL RECOGNITION PARTICLE; SINGLE CHAIN RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR;

ANTIGEN RECOGNITION; ARTHRITIS; AUTOPHOSPHORYLATION; BIOLOGY; BLEEDING; CROHN DISEASE; DIMERIZATION; DRUG DESIGN; GENE TARGETING; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MEDICINE; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; THROMBOCYTE; THROMBOSIS; ULCERATIVE COLITIS; VIRUS INFECTION; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; CELL MEMBRANE; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL MEMBRANE; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 77953588437     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.4.2.10746     Document Type: Review

References (108)

1. Rudd CE. Disabled receptor signaling and new primary immunodeficiency disorders. N Engl J Med 2006; 354:1874-7.
2. Sigalov AB, ed. Multichain Immune Recognition Receptor Signaling: From Spatiotemporal Organization to Human Disease. New York: Springer-Verlag 2008.
3. Keegan AD, Paul WE. Multichain immune recognition receptors: similarities in structure and signaling pathways. Immunol Today 1992; 13:63-8.
4. Sigalov AB. Immune cell signaling: a novel mechanistic model reveals new therapeutic targets. Trends Pharmacol Sci 2006; 27:518-24.
5. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995; 80:213-23.
6. Hubbard SR. Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol 1999; 71:343-58.
7. Weiss A, Schlessinger J. Switching signals on or off by receptor dimerization. Cell 1998; 94:277-80.
8. Schlessinger J. Signal transduction. Autoinhibition control. Science 2003; 300:750-2.
9. Siegel RM, Muppidi JR, Sarker M, Lobito A, Jen M, Martin D, et al. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol 2004; 167:735-44.
10. Chan FK. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 2007; 37:101-7.
11. Chan KF, Siegel MR, Lenardo JM. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 2000; 13:419-22.
12. Sigalov AB. Multichain immune recognition receptor signaling: different players, same game? Trends Immunol 2004; 25:583-9.
13. Schamel WW, Arechaga I, Risueno RM, van Santen HM, Cabezas P, Risco C, et al. Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. J Exp Med 2005; 202:493-503.
14. Berlanga O, Bori-Sanz T, James JR, Frampton J, Davis SJ, Tomlinson MG, et al. Glycoprotein VI oligomerization in cell lines and platelets. J Thromb Haemost 2007; 5:1026-33.
15. Sigalov A. Multi-chain immune recognition receptors: spatial organization and signal transduction. Semin Immunol 2005; 17:51-64.
16. Sigalov AB. Signaling chain homooligomerization (SCHOOL) model. Adv Exp Med Biol 2008; 640:121-63.
17. Sigalov A, Aivazian D, Stern L. Homooligomerization of the cytoplasmic domain of the T cell receptor zeta chain and of other proteins containing the immunoreceptor tyrosine-based activation motif. Biochemistry 2004; 43:2049-61.
18. Sigalov AB, Zhuravleva AV, Orekhov VY. Binding of intrinsically disordered proteins is not necessarily accompanied by a structural transition to a folded form. Biochimie 2007; 89:419-1.
19. Loregian A, Palu G. Disruption of protein-protein interactions: towards new targets for chemotherapy. J Cell Physiol 2005; 204:750-62.
20. Hershberger SJ, Lee SG, Chmielewski J. Scaffolds for blocking protein-protein interactions. Curr Top Med Chem 2007; 7:928-42.
21. Sillerud LO, Larson RS. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr Protein Pept Sci 2005; 6:151-69.
22. Norman PS. Immunotherapy: 1999-2004. J Allergy Clin Immunol 2004; 113:1013-23.
23. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2003; 2:775-89.
24. Kepley CL. New approaches to allergen immunotherapy. Curr Allergy Asthma Rep 2006; 6:427-33.
25. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7:365-78.
26. McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacol Sci 2003; 93:381-96.
27. Molloy PE, Sewell AK, Jakobsen BK. Soluble T cell receptors: novel immunotherapies. Curr Opin Pharmacol 2005; 5:438-43.
28. Pons L, Burks W. Novel treatments for food allergy. Expert Opin Investig Drugs 2005; 14:829-34.
29. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7:622-32.
30. St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, et al. New reagents on the horizon for immune tolerance. Annu Rev Med 2007; 58:329-46.
31. Hombach A, Heuser C, Abken H. The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr Gene Ther 2002; 2:211-26.
32. Luzak B, Golanski J, Rozalski M, Bonclerand MA, Watala C. Inhibition of collagen-induced platelet reactivity by DGEA peptide. Acta Biochim Pol 2003; 50:1119-28. (Pubitemid 38608840)
33. O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, et al. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol 2001; 167:2555-60. (Pubitemid 32768882)
34. Andrasfalvy M, Peterfy H, Toth G, Matko J, Abramson J, Kerekes K, et al. The beta subunit of the type I Fcepsilon receptor is a target for peptides inhibiting IgE-mediated secretory response of mast cells. J Immunol 2005; 175:2801-6. (Pubitemid 41170496)
35. Cronin SJ, Penninger JM. From T-cell activation signals to signaling control of anti-cancer immunity. Immunol Rev 2007; 220:151-68.
36. Waldmann TA. Immune receptors: targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection. Annu Rev Immunol 1992; 10:675-704.
37. Sigalov AB. Transmembrane interactions as immunotherapeutic targets: lessons from viral pathogenesis. Adv Exp Med Biol 2007; 601:335-44.
38. Sigalov AB. Interaction between HIV gp41 fusion peptide and T cell receptor: putting the puzzle pieces back together. Faseb J 2007; 21:1633-4.
39. Sigalov AB. More on: glycoprotein VI oligomerization: a novel concept of platelet inhibition. J Thromb Haemost 2007; 5:2310-2.
40. Sigalov AB. SCHOOL model and new targeting strategies. Adv Exp Med Biol 2008; 640:268-311.
41. Sigalov AB. Novel mechanistic concept of platelet inhibition. Expert Opin Ther Targets 2008; 12:677-92.
42. Sigalov AB. Novel mechanistic insights into viral modulation of immune receptor signaling. PLoS Pathog 2009; 5:1000404.
43. Sigalov AB. Protein intrinsic disorder and oligomericity in cell signaling. Mol Biosyst 2010, 6:451-61.
44. Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, Cremel G, et al. Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol Biol Cell 2004; 15:3464-74.
45. Bennasroune A, Gardin A, Auzan C, Clauser E, Dirrig-Grosch S, Meira M, et al. Inhibition by transmembrane peptides of chimeric insulin receptors. Cell Mol Life Sci 2005; 62:2124-31.
46. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, et al. A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 1996; 271:16384-92.
47. George SR, Lee SP, Varghese G, Zeman PR, Seeman P, Ng GY, et al. A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. J Biol Chem 1998; 273:30244-8.
48. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125:1137-49.
49. Jiang G, Hunter T. Receptor signaling: when dimerization is not enough. Curr Biol 1999; 9:568-71.
50. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998; 395:511-6.
51. Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, You Y, et al. An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol 1998; 5:993-1004.
52. Ballinger MD, Wells JA. Will any dimer do? Nat Struct Biol 1998; 5:938-40.
53. Gay NJ, Gangloff M, Weber AN. Toll-like receptors as molecular switches. Nat Rev Immunol 2006; 6:693-8.
54. Neiditch MB, Federle MJ, Pompeani AJ, Kelly RC, Swem DL, Jeffrey PD, et al. Ligand-induced asymmetry in histidine sensor kinase complex regulates quorum sensing. Cell 2006; 126:1095-108.
55. Lofts FJ, Hurst HC, Sternberg MJ, Gullick WJ. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene 1993; 8:2813-20.
56. Call ME, Pyrdol J, Wiedmann M, Wucherpfennig KW. The organizing principle in the formation of the T cell receptor-CD3 complex. Cell 2002; 111:967-79.
57. Manolios N, Bonifacino JS, Klausner RD. Transmembrane helical interactions and the assembly of the T cell receptor complex. Science 1990; 249:274-7. (Pubitemid 20232085)
58. Kim WM, Sigalov AB. Viral pathogenesis, modulation of immune receptor signaling and treatment. Adv Exp Med Biol 2008; 640:325-49.
59. Manolios N, Collier S, Taylor J, Pollard J, Harrison LC, Bender V. T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease. Nat Med 1997; 3:84-8.
60. Gollner GP, Muller G, Alt R, Knop J, Enk AH. Therapeutic application of T cell receptor mimic peptides or cDNA in the treatment of T cell-mediated skin diseases. Gene Ther 2000; 7:1000-4. (Pubitemid 30398347)
61. Amon MA, Ali M, Bender V, Chan YN, Toth I, Manolios N. Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function. Biochim Biophys Acta 2006; 1763:879-88.
62. Collier S, Bolte A, Manolios N. Discrepancy in CD3-transmembrane peptide activity between in vitro and in vivo T-cell inhibition. Scand J Immunol 2006; 64:388-91.
63. Ali M, De Planque MRR, Huynh NT, Manolios N, Separovic F. Biophysical studies of a transmembrane peptide derived from the T cell antigen receptor. Letters in Peptide Science 2002; 8:227-33.
64. Wang XM, Djordjevic JT, Kurosaka N, Schibeci S, Lee L, Williamson P, et al. T-cell antigen receptor peptides inhibit signal transduction within the membrane bilayer. Clin Immunol 2002; 105:199-207.
65. Huynh NT, Ffrench RA, Boadle RA, Manolios N. Transmembrane T-cell receptor peptides inhibit B- and natural killer-cell function. Immunology 2003; 108:458-64.
66. Bender V, Ali M, Amon M, Diefenbach E, Manolios N. T cell antigen receptor peptide-lipid membrane interactions using surface plasmon resonance. J Biol Chem 2004; 279:54002-7.
67. Gerber D, Quintana FJ, Bloch I, Cohen IR, Shai Y. D-enantiomer peptide of the TCRalpha transmembrane domain inhibits T-cell activation in vitro and in vivo. Faseb J 2005; 19:1190-2.
68. Enk AH, Knop J. T cell receptor mimic peptides and their potential application in T-cell-mediated disease. Int Arch Allergy Immunol 2000; 123:275-81.
69. Manolios N, Huynh NT, Collier S. Peptides in the treatment of inflammatory skin disease. Australas J Dermatol 2002; 43:226-7.
70. Ali M, Amon M, Bender V, Manolios N. Hydrophobic transmembrane-peptide lipid conjugations enhance membrane binding and functional activity in T-cells. Bioconjug Chem 2005; 16:1556-63.
71. Wang XM, Djordjevic JT, Bender V, Manolios N. T cell antigen receptor (TCR) transmembrane peptides colocalize with TCR, not lipid rafts, in surface membranes. Cell Immunol 2002; 215:12-9.
72. Kurosaka N, Bolte A, Ali M, Manolios N. T-cell antigen receptor assembly and cell surface expression is not affected by treatment with T-cell antigen receptor-alpha chain transmembrane Peptide. Protein Pept Lett 2007; 14:299-303.
73. Vandebona H, Ali M, Amon M, Bender V, Manolios N. Immunoreceptor transmembrane peptides and their effect on natural killer (NK) cell cytotoxicity. Protein Pept Lett 2006; 13:1017-24.
74. Luton F, Buferne M, Legendre V, Chauvet E, Boyer C, Schmitt-Verhulst AM. Role of CD3gamma and CD3delta cytoplasmic domains in cytolytic T lymphocyte functions and TCR/CD3 downmodulation. J Immunol 1997; 158:4162-70.
75. Roifman CM. CD3delta immunodeficiency. Curr Opin Allergy Clin Immunol 2004; 4:479-84.
76. Jung SM, Moroi M. Platelet glycoprotein VI. Adv Exp Med Biol 2008; 640:53-63.
77. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 2007; 8:171-8.
78. + T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 2007; 132:2346-58.
79. + T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 2008; 294:199-207.
80. Kjellev S, Haase C, Lundsgaard D, Urso B, Tornehave D, Markholst H. Inhibition of NKG2D receptor function by antibody therapy attenuates transfer-induced colitis in SCID mice. Eur J Immunol 2007; 37:1397-406.
81. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000; 164:4991-5. (Pubitemid 30305166)
82. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006; 7:1266-73.
83. Murakami Y, Akahoshi T, Aoki N, Toyomoto M, Miyasaka N, Kohsaka H. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis Rheum 2009; 60:1615-23.
84. Quintana FJ, Gerber D, Kent SC, Cohen IR, Shai Y. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest 2005; 115:2149-58.
85. Bloch I, Quintana FJ, Gerber D, Cohen T, Cohen IR, Shai Y. T-Cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif. Faseb J 2007; 21:393-401.
86. Bosch ML, Earl PL, Fargnoli K, Picciafuoco S, Giombini F, Wong-Staal F, et al. Identification of the fusion peptide of primate immunodeficiency viruses. Science 1989; 244:694-7. (Pubitemid 19147680)
87. Gallaher WR. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 1987; 50:327-8.
88. Kurosaka N, Ali M, Byth K, Manolios N. The mode of anti-arthritic peptide delivery impacts on the severity and outcome of adjuvant induced arthritis. APLAR J Rheumatol 2007; 10:198-203.
89. Manolios N, Ali M, Amon M, Bender V. Therapeutic application of transmembrane T and natural killer cell receptor peptides. Adv Exp Med Biol 2008; 640:208-19.
90. Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 1985; 230:453-5. (Pubitemid 16192559)
91. Ruegg CL, Monell CR, Strand M. Identification, using synthetic peptides, of the minimum amino acid sequence from the retroviral transmembrane protein p15E required for inhibition of lymphoproliferation and its similarity to gp21 of human T-lymphotropic virus types I and II. J Virol 1989; 63:3250-6. (Pubitemid 19181380)
92. Ruegg CL, Monell CR, Strand M. Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1. J Virol 1989; 63:3257-60. (Pubitemid 19181381)
93. Yaddanapudi K, Palacios G, Towner JS, Chen I, Sariol CA, Nichol ST, et al. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. Faseb J 2006; 20:2519-30.
94. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005; 6:515-23.
95. Sullivan BM, Coscoy L. Downregulation of the T-cell receptor complex and impairment of T-cell activation by human herpesvirus 6 u24 protein. J Virol 2008; 82:602-8.
96. Min CK, Bang SY, Cho BA, Choi YH, Yang JS, Lee SH, et al. Role of amphipathic helix of a herpesviral protein in membrane deformation and T cell receptor downregulation. PLoS Pathog 2008; 4:1000209.
97. Park J, Lee BS, Choi JK, Means RE, Choe J, Jung JU. Herpesviral protein targets a cellular WD repeat endosomal protein to downregulate T lymphocyte receptor expression. Immunity 2002; 17:221-33.
98. Kikuta H, Lu H, Tomizawa K, Matsumoto S. Enhancement of human herpesvirus 6 replication in adult human lymphocytes by monoclonal antibody to CD3. J Infect Dis 1990; 161:1085-7. (Pubitemid 20177864)
99. Roffman E, Frenkel N. Replication of human herpesvirus-6 in thymocytes activated by anti-CD3 antibody. J Infect Dis 1991; 164:617-8.
100. + T cell depletion. J Clin Immunol 2001; 21:218-26.
101. Melnyk RA, Partridge AW, Yip J, Wu Y, Goto NK, Deber CM. Polar residue tagging of transmembrane peptides. Biopolymers 2003; 71:675-85.
102. Smith SO, Smith C, Shekar S, Peersen O, Ziliox M, Aimoto S. Transmembrane interactions in the activation of the Neu receptor tyrosine kinase. Biochemistry 2002; 41:9321-32.
103. Cunningham F, Deber CM. Optimizing synthesis and expression of transmembrane peptides and proteins. Methods 2007; 41:370-80.
104. Yin H, Slusky JS, Berger BW, Walters RS, Vilaire G, Litvinov RI, et al. Computational design of peptides that target transmembrane helices. Science 2007; 315:1817-22.
105. Wimley WC, White SH. Designing transmembrane alpha-helices that insert spontaneously. Biochemistry 2000; 39:4432-42.
106. Edwards RJ, Moran N, Devocelle M, Kiernan A, Meade G, Signac W, et al. Bioinformatic discovery of novel bioactive peptides. Nat Chem Biol 2007; 3:108-12.
107. Ashish, Wimley WC. Visual detection of specific, native interactions between soluble and microbead-tethered alpha-helices from membrane proteins. Biochemistry 2001; 40:13753-9.
108. Killian JA. Synthetic peptides as models for intrinsic membrane proteins. FEBS Lett 2003; 555:134-8.